Dimensional Fund Advisors’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.28M | Sell |
921,923
-649,089
| -41% | -$892K | ﹤0.01% | 2795 |
|
|
2025
Q4 | $2.53M | Sell |
1,571,012
-195,679
| -11% | -$410K | ﹤0.01% | 2689 |
|
|
2025
Q3 | $4.82M | Buy |
1,766,691
+884,590
| +100% | +$2.94M | ﹤0.01% | 2556 |
|
|
2025
Q2 | $3.21M | Buy |
882,101
+346,670
| +65% | +$953K | ﹤0.01% | 2633 |
|
|
2025
Q1 | $1.03M | Buy |
535,431
+409,751
| +326% | +$836K | ﹤0.01% | 2878 |
|
|
2024
Q4 | $239K | Buy |
+125,680
| New | +$218K | ﹤0.01% | 3139 |
|
|
2022
Q4 | – | Sell |
-627,549
| Closed | -$199K | – | 3492 |
|
|
2022
Q3 | $199K | Sell |
627,549
-155,126
| -20% | -$60.9K | ﹤0.01% | 3237 |
|
|
2022
Q2 | $276K | Sell |
782,675
-1,884,186
| -71% | -$791K | ﹤0.01% | 3195 |
|
|
2022
Q1 | $1.92M | Buy |
2,666,861
+73,020
| +3% | +$156K | ﹤0.01% | 2845 |
|
|
2021
Q4 | $5.86M | Buy |
2,593,841
+498,078
| +24% | +$1.36M | ﹤0.01% | 2514 |
|
|
2021
Q3 | $6.04M | Sell |
2,095,763
-1,309,358
| -38% | -$3.74M | ﹤0.01% | 2525 |
|
|
2021
Q2 | $12.9M | Buy |
3,405,121
+972,862
| +40% | +$3.27M | ﹤0.01% | 2243 |
|
|
2021
Q1 | $8.23M | Buy |
2,432,259
+684,955
| +39% | +$2.47M | ﹤0.01% | 2406 |
|
|
2020
Q4 | $4.89M | Sell |
1,747,304
-10,432
| -0.6% | -$30.5K | ﹤0.01% | 2536 |
|
|
2020
Q3 | $4.41M | Sell |
1,757,736
-141,985
| -7% | -$1.25M | ﹤0.01% | 2483 |
|
|
2020
Q2 | $25.8M | Buy |
1,899,721
+55,298
| +3% | +$572K | 0.01% | 1721 |
|
|
2020
Q1 | $14M | Buy |
1,844,423
+286,869
| +18% | +$2.23M | 0.01% | 1944 |
|
|
2019
Q4 | $9.84M | Buy |
1,557,554
+301,930
| +24% | +$1.44M | ﹤0.01% | 2356 |
|
|
2019
Q3 | $4.92M | Buy |
1,255,624
+203,888
| +19% | +$874K | ﹤0.01% | 2604 |
|
|
2019
Q2 | $5.09M | Buy |
1,051,736
+162,755
| +18% | +$926K | ﹤0.01% | 2627 |
|
|
2019
Q1 | $7.28M | Sell |
888,981
-53,618
| -6% | -$368K | ﹤0.01% | 2518 |
|
|
2018
Q4 | $5.21M | Buy |
942,599
+488,972
| +108% | +$3.83M | ﹤0.01% | 2597 |
|
|
2018
Q3 | $4.01M | Buy |
+453,627
| New | +$4.06M | ﹤0.01% | 2745 |
|
|
2017
Q4 | – | Sell |
-35,572
| Closed | -$700K | – | 3324 |
|
|
2017
Q3 | $700K | Hold |
35,572
| – | – | ﹤0.01% | 3058 |
|
|
2017
Q2 | $511K | Hold |
35,572
| – | – | ﹤0.01% | 3086 |
|
|
2017
Q1 | $327K | Sell |
35,572
-3,391
| -9% | -$33.1K | ﹤0.01% | 3153 |
|
|
2016
Q4 | $406K | Buy |
38,963
+1,464
| +4% | +$12.6K | ﹤0.01% | 3121 |
|
|
2016
Q3 | $339K | Buy |
37,499
+12,527
| +50% | +$106K | ﹤0.01% | 3122 |
|
|
2016
Q2 | $187K | Sell |
24,972
-93
| -0.4% | -$812 | ﹤0.01% | 3187 |
|
|
2016
Q1 | $226K | Buy |
25,065
+4,300
| +21% | +$34.9K | ﹤0.01% | 3166 |
|
|
2015
Q4 | $268K | Buy |
+20,765
| New | +$212K | ﹤0.01% | 3180 |
|
Other funds holding AKBA
VCM
VPM
Dimensional Fund Advisors's AKBA Position: Q1 2026 in Review
Dimensional Fund Advisors reduced its Akebia Therapeutics (AKBA) stake by 41% in Q1 2026, selling an estimated $892K and leaving 921,923 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2795.
Dimensional Fund Advisors first reported a position in AKBA in Q4 2015 and has held it in 31 quarters since. The position peaked at $25.8M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Dimensional Fund Advisors held 921,923 shares of Akebia Therapeutics worth $1.28M as of Q1 2026.
- Dimensional Fund Advisors sold 649,089 Akebia Therapeutics shares in Q1 2026, an estimated $892K.
- Akebia Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #2795 holding.
- Dimensional Fund Advisors first reported a position in Akebia Therapeutics in Q4 2015 and has held it in 31 quarters since.
- Dimensional Fund Advisors's Akebia Therapeutics position peaked at $25.8M in Q2 2020.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.